ATE506614T1 - Gfats als modifikatoren des axin-wegs und verwendungsverfahren - Google Patents

Gfats als modifikatoren des axin-wegs und verwendungsverfahren

Info

Publication number
ATE506614T1
ATE506614T1 AT06785181T AT06785181T ATE506614T1 AT E506614 T1 ATE506614 T1 AT E506614T1 AT 06785181 T AT06785181 T AT 06785181T AT 06785181 T AT06785181 T AT 06785181T AT E506614 T1 ATE506614 T1 AT E506614T1
Authority
AT
Austria
Prior art keywords
methods
axin
gfats
axin pathway
pathway modifiers
Prior art date
Application number
AT06785181T
Other languages
English (en)
Inventor
Steven Gendreau
Emery Dora
Kim Lickteig
Original Assignee
Exelixis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exelixis Inc filed Critical Exelixis Inc
Application granted granted Critical
Publication of ATE506614T1 publication Critical patent/ATE506614T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57545—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the ovaries
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57515—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5752—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the lungs
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57525—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the liver or pancreas
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57535—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the large intestine, e.g. colon, rectum or anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/91188—Transferases (2.) transferring nitrogenous groups (2.6)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AT06785181T 2005-06-20 2006-06-20 Gfats als modifikatoren des axin-wegs und verwendungsverfahren ATE506614T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US69231605P 2005-06-20 2005-06-20
PCT/US2006/023971 WO2007002081A2 (en) 2005-06-20 2006-06-20 Gfats as modifiers of the axin pathway and methods of use

Publications (1)

Publication Number Publication Date
ATE506614T1 true ATE506614T1 (de) 2011-05-15

Family

ID=37595742

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06785181T ATE506614T1 (de) 2005-06-20 2006-06-20 Gfats als modifikatoren des axin-wegs und verwendungsverfahren

Country Status (8)

Country Link
US (1) US20110167505A1 (de)
EP (1) EP1899487B1 (de)
JP (1) JP2008546409A (de)
AT (1) ATE506614T1 (de)
AU (1) AU2006262364A1 (de)
CA (1) CA2612143A1 (de)
DE (1) DE602006021421D1 (de)
WO (1) WO2007002081A2 (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112980914A (zh) * 2019-12-12 2021-06-18 中国科学院大连化学物理研究所 Gfpt1基因作为靶点在筛选抗肿瘤药物中的应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6506607B1 (en) * 1997-12-24 2003-01-14 Millennium Pharmaceuticals, Inc. Methods and compositions for the identification and assessment of prostate cancer therapies and the diagnosis of prostate cancer
JP4601143B2 (ja) * 2000-06-13 2010-12-22 大塚製薬株式会社 新規酵素遺伝子およびその発現産物
US20060121457A1 (en) * 2001-06-05 2006-06-08 Exelixis, Inc. Gfats as modifiers of the p53 pathway and methods of use
EP1492523A2 (de) * 2001-11-23 2005-01-05 Chugai Seiyaku Kabushiki Kaisha Verfahren zur bestimmung von enzymen die tumoren als ziel haben
AU2003257199A1 (en) * 2002-08-06 2004-02-23 Exelixis, Inc. Maxs as modifiers of the axin pathway and methods of use
EP1535067A4 (de) * 2002-08-06 2007-06-20 Exelixis Inc Papsss als modifikatoren des axin-wegs und verwendungsverfahren
JP2006502736A (ja) * 2002-10-17 2006-01-26 ファルマシア・コーポレーション Ｇｆａｔ発現のアンチセンス調節
WO2004047754A2 (en) * 2002-11-25 2004-06-10 Exelixis, Inc. Loc169505 as modifier of the apc and axin pathways and methods of use
JP2006517395A (ja) * 2002-12-30 2006-07-27 エクセリクシス， インク． Ａｘｉｎ経路のモディファイヤーとしてのｆｌｊ１０６０７および使用方法
WO2004066948A2 (en) * 2003-01-29 2004-08-12 Exelixis Inc. Mapcaxs as modifiers of the apc and axin pathways and methods of use
EP1592780A4 (de) * 2003-02-11 2008-11-05 Exelixis Inc Dyrks als modifikatoren des apc- und des axin-wegs sowie verwendungsverfahren

Also Published As

Publication number Publication date
WO2007002081A2 (en) 2007-01-04
EP1899487A2 (de) 2008-03-19
DE602006021421D1 (de) 2011-06-01
EP1899487B1 (de) 2011-04-20
AU2006262364A1 (en) 2007-01-04
CA2612143A1 (en) 2007-01-04
EP1899487A4 (de) 2008-10-22
JP2008546409A (ja) 2008-12-25
US20110167505A1 (en) 2011-07-07
WO2007002081A3 (en) 2007-04-26

Similar Documents

Publication Publication Date Title
ATE483976T1 (de) Gfats als modifikatoren des p53-wegs und verwendungsverfahren
ATE489628T1 (de) Galk1s als modifikatoren des pten/akt-wegs
ATE536549T1 (de) Galnts als modifikatoren des igfr-weges und verwendungsverfahren
ATE506614T1 (de) Gfats als modifikatoren des axin-wegs und verwendungsverfahren
ATE494551T1 (de) C20orf23 als modifikator des igfr-wegs und verwendungsverfahren
WO2006009947A3 (en) Migfs as modifiers of the igf pathway and methods of use
WO2004066948A3 (en) Mapcaxs as modifiers of the apc and axin pathways and methods of use
ATE469175T1 (de) Prkcs als modifikatoren des beta catenin pfads und anwendungsverfahren
WO2004013309A3 (en) PAPSSs AS MODIFIERS OF THE AXIN PATHWAY AND METHODS OF USE
WO2008036422A3 (en) Vipr1s as modifiers of the e2f/rb pathway and methods of use
WO2004024882A3 (en) FLJ20647s AS MODIFIERS OF THE p21 PATHWAY AND METHODS OF USE
WO2005072475A3 (en) Itpks as modifiers of the igfr pathway and methods of use
WO2006036613A3 (en) Mracs as modifiers of the rac pathway and methods of use
WO2006009960A3 (en) Hdacs as modifiers of the rb pathway and methods of use
WO2005090992A3 (en) Mptens as modifiers of the pten pathway and methods of use
WO2007058933A3 (en) Melks as modifiers of the rho pathway and methods of use
WO2006099182A3 (en) Mptenakts as modifiers of the pten/akt pathway and methods of use
WO2005072470A3 (en) Mbms as modifiers of branching morphogenesis and methods of use
WO2004015071A3 (en) CSNK1GS AS MODIFIERS OF THE p21 PATHWAY AND METHODS OF USE
WO2005123111A3 (en) Maxs as modifiers of the axin pathway and methods of use
WO2004083389A3 (en) Mbcats as modifiers of the beta-catenin pathway and methods of use
WO2004067722A3 (en) Facls as modifiers of the rb pathway and methods of use
WO2004104168A3 (en) Mrbs as modifiers of the rb pathway and methods of use
WO2004067721A3 (en) Tkts as modifiers of the beta-catenin pathway and methods of use
WO2004083447A3 (en) Mbcats as modifiers of the beta-catenin pathway and methods of use

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties